RxDoctor Payments Data

Russell Havranek, MD

Gastroenterology · San Antonio, TXNPI 1871672519

Payments from drug & device makers

$244,655in general payments, 2019–2025

Across 718 payments — averaging $340.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$88K
  • E.r. Squibb & Sons, L.L.C.$73K
  • AstraZeneca$56K
  • AbbVie$21K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$1K
  • plus $5K from 36 others
$1,735in research payments, 2019–2025

Across 2 payments — averaging $867.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Food & beverage$10,61898%
  • Education$2072%
  • Entertainment$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$244,655 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$305,427
Medicare patients
602
Services billed
9,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$473,223
CreonLipase/Protease/Amylase15$28,961
ViberziEluxadoline15$21,975
LinzessLinaclotide24$14,577
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates202$12,116
Trientine Hcl12$10,075
Dexlansoprazole DrDexlansoprazole32$7,497
Budesonide DrBudesonide21$6,671
Omeprazole245$2,802
ClenpiqSod Picosulf/Mag Ox/Citric Ac15$2,592
Mesalamine ErMesalamine17$2,404
Lubiprostone18$2,363
Pantoprazole Sodium126$1,935
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine48$1,484
Colesevelam Hcl12$1,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,114$473,22317 claims
AbbVieCreon, Viberzi, Linzess$20,533$65,51254 claims
Ferring Pharmaceuticals Inc.Clenpiq$12$2,59215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →